Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy

Item

http://www.wikidata.org/entity/Q58294593

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2012

@uk

name

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@en

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@nl

type

Item

label

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@en

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@nl

prefLabel

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@en

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@nl

P1476

Oxidative stress improvement i ...... ergoing lipid-lowering therapy

@en

P2093

Andrea Ercole Satta

http://www.w3.org/2001/XMLSchema#string

Giacomina Loriga

http://www.w3.org/2001/XMLSchema#string

Luca Deiana

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

N-methyl-D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement.

Plasma thiols redox status by laser-induced fluorescence capillary electrophoresis.

Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications.

Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease.

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

P2888

s00726-012-1223-0

P304

1499-1507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00726-012-1223-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Salvatore Sotgia

Ciriaco Carru

Angelo Zinellu

P577

2012-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22278741

http://www.w3.org/2001/XMLSchema#string